# Sorachai Nitayaphan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/925944/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 49<br>papers | 2,087<br>citations | 361413<br>20<br>h-index | 243625<br>44<br>g-index |
| 51<br>all docs | 51<br>docs citations | 51<br>times ranked | 3062<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcÎ³R Complex Formation After Vaccination. Frontiers in Immunology, 2022, 13, 820148. | 4.8 | 1 |
| 2 | HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS Pathogens, 2022, 18, e1010369. | 4.7 | 5 |
| 3 | Factors influencing estimates of HIV-1 infection timing using BEAST. PLoS Computational Biology, 2021, 17, e1008537. | 3.2 | 4 |
| 4 | Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. EClinicalMedicine, 2021, 38, 101033. | 7.1 | 4 |
| 5 | Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Journal of Virology, 2021, 95, e0079721. | 3.4 | 2 |
| 6 | Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. ELife, 2021, 10, . | 6.0 | 12 |
| 7 | A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. Cell Reports Medicine, 2021, 2, 100386. | 6.5 | 8 |
| 8 | Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays. AIDS Research and Human Retroviruses, 2020, 36, 583-589. | 1.1 | 9 |
| 9 | Longitudinal Analysis of Peripheral and Colonic CD161+ CD4+ T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation. Viruses, 2020, 12, 1426. | 3.3 | 3 |
| 10 | Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV,the, 2020, 7, e238-e248. | 4.7 | 33 |
| 11 | Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. PLoS Pathogens, 2020, 16, e1008179. | 4.7 | 24 |
| 12 | Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. Nature Communications, 2020, 11, 272. | 12.8 | 38 |
| 13 | Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight, 2020, 5, . | 5.0 | 12 |
| 14 | Global variability of the human IgG glycome. Aging, 2020, 12, 15222-15259. | 3.1 | 37 |
| 15 | Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 2019, 11, 607. | 3.3 | 12 |
| 16 | Expansion of Stem Cell-Like CD4<sup>+</sup>Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. Journal of Virology, 2019, 93, . | 3.4 | 11 |
| 17 | Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. Journal of Virology, 2018, 92, . | 3.4 | 3 |
| 18 | Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathogens, 2018, 14, e1006888. | 4.7 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. Scientific Reports, 2017, 7, 1057. | 3.3 | 10 |
| 20 | Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263. | 4.0 | 57 |
| 21 | Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428. | 2.5 | 12 |
| 22 | Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathogens, 2017, 13, e1006510. | 4.7 | 63 |
| 23 | V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS ONE, 2017, 12, e0180720. | 2.5 | 55 |
| 24 | Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. New England Journal of Medicine, 2016, 374, 2120-2130. | 27.0 | 229 |
| 25 | Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. Journal of Virology, 2016, 90, 4005-4016. | 3.4 | 25 |
| 26 | Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS ONE, 2015, 10, e0127998. | 2.5 | 2 |
| 27 | COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616. | 17.5 | 232 |
| 28 | Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. PLoS Computational Biology, 2015, 11, e1003973. | 3.2 | 51 |
| 29 | Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees. PLoS Computational Biology, 2015, 11, e1004185. | 3.2 | 50 |
| 30 | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Research and Human Retroviruses, 2015, 31, 1178-1186. | 1.1 | 14 |
| 31 | HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nature Medicine, 2015, 21, 1139-1141. | 30.7 | 50 |
| 32 | Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722. | 6.1 | 13 |
| 33 | Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E. PLoS ONE, 2015, 10, e0115582. | 2.5 | 10 |
| 34 | Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to Î±4Î²7 Integrin Receptor. PLoS ONE, 2015, 10, e0143895. | 2.5 | 41 |
| 35 | Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78. | 2.0 | 26 |
| 36 | HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726. | 3.4 | 169 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Immune Correlates Identified in the RV144 Vaccine Efficacy Trial Impact HIV-1 Acquisition Only in the Presence of Certain HLA Class II Genes. AIDS Research and Human Retroviruses, 2014, 30, A40-A40. | 1.1 | 0 |
| 38 | Sex Differences in Immune Variables in the RV144 Trial. AIDS Research and Human Retroviruses, 2014, 30, A191-A191. | 1.1 | 0 |
| 39 | Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. AIDS Research and Human Retroviruses, 2014, 30, A58-A58. | 1.1 | 2 |
| 40 | Evaluation of Mucosal Tissue Explants as Ex Vivo Surrogates of In Vivo Vaccination of Non-human Primates (NHPs) and Humans. AIDS Research and Human Retroviruses, 2014, 30, A24-A24. | 1.1 | 1 |
| 41 | HIVâ€specific antibodyâ€dependent phagocytosis matures during HIV infection. Immunology and Cell Biology, 2014, 92, 679-687. | 2.3 | 29 |
| 42 | Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417. | 3.4 | 16 |
| 43 | HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics, 2014, 66, 299-310. | 2.4 | 14 |
| 44 | Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. PLoS ONE, 2014, 9, e87572. | 2.5 | 248 |
| 45 | CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants. PLoS ONE, 2014, 9, e111334. | 2.5 | 9 |
| 46 | Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. Journal of Infectious Diseases, 2012, 206, 431-441. | 4.0 | 273 |
| 47 | HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Review of Vaccines, 2012, 11, 805-819. | 4.4 | 10 |
| 48 | Safety and Immunogenicity of an HIV Subtype B and E Primeâ€Boost Vaccine Combination in HIVâ€Negative Thai Adults. Journal of Infectious Diseases, 2004, 190, 702-706. | 4.0 | 128 |
| 49 | Unique HIV Risk Factors and Prevention Needs for Transgender Women and Cisgender Men Who Have Sex with Men in Bangkok, Thailand. Transgender Health, 0, , . | 2.5 | 0 |